Build-3 trial bosentan

Cited by: articles PMID: King TE. Curr Opin Investig Drugs , 9 11 , 01 Nov Cited by: 4 articles PMID: Cottin V. Eur Respir Rev , 21 , 01 Jun Cited by: 23 articles PMID: Contact us. Europe PMC requires Javascript to function effectively. Recent Activity. Search life-sciences literature Over 39 million articles, preprints and more Search Advanced search.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract Available from publisher site using DOI. A subscription may be required. King TE Jr 1 ,. Brown KK ,. Ganesh Raghu Search articles by 'Ganesh Raghu'. Raghu G ,. Lynch DA ,. Fernando Martinez Search articles by 'Fernando Martinez'. Martinez F ,. Dominique Valeyre Search articles by 'Dominique Valeyre'. Valeyre D ,. Isabelle Leconte Search articles by 'Isabelle Leconte'. Leconte I ,. Adele Morganti Search articles by 'Adele Morganti'. Morganti A ,. Roux S ,. Juergen Behr Search articles by 'Juergen Behr'.

Behr J. Affiliations 1 author 1. A comment on this article appears in " End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. Share this article Share with email Share with twitter Share with linkedin Share with facebook. Recent pulmonary or upper respiratory tract infection up to 4 weeks prior to randomization. Acute or chronic impairment other than dyspnea limiting the ability to comply with study requirements. Moderate to severe hepatic impairment.

Pregnancy or breast-feeding. Current drug or alcohol dependence. Oral anticoagulants other than those indicated for a venous or arterial thrombotic disease. Treatment with glibenclamide glyburide and calcineurin inhibitors cyclosporine A, tacrolimus up to 1 week prior to randomization. Treatment with an endothelin receptor antagonist up to 3 months prior to randomization.

Treatment with another investigational drug up to 3 months prior to randomization or planned treatment. Known hypersensitivity to bosentan or any of the excipients. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.

John's-Eastern Health St. More Information. Publications automatically indexed to this study by ClinicalTrials. BUILD a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Epub Apr 7. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Idiopathic Pulmonary Fibrosis. Drug: Bosentan Drug: Placebo.

Phase 3. Study Type :. Interventional Clinical Trial. Results Point of Contact. Publications automatically indexed to this study by ClinicalTrials. BUILD a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Epub Apr 7. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Idiopathic Pulmonary Fibrosis. Drug: Bosentan Drug: Placebo. Pre-assignment Details. Period Title: Overall Study. Total of all reporting groups. Baseline Analysis Population Description. Korea, Republic of. Disease worsening was defined as an event of worsening of pulmonary fu